MBRX
Moleculin Biotech, Inc.
Biotechnology
Market Cap$29M
5Y Perf.-97.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MBRX vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
MBRX vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MBRX | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $29M | $1712.35T |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-24M | $-168M |
| Total Debt | $222K | $22M |
| Cash & Equiv. | $9M | $194M |
MBRX vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MBRX
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Moleculin Biotech, … (MBRX) | 100 | 2.5 | -97.5% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MBRX vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MBRX leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
MBRX
Moleculin Biotech, Inc.
The Income Pick
MBRX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.22, yield 0.4%
- EPS growth 82.0%
- Lower volatility, beta 1.22, Low D/E 1.5%, current ratio 1.41x
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Long-Run Compounder
DBVT is the clearest fit if your priority is long-term compounding.
- -87.0% 10Y total return vs MBRX's -99.7%
- -89.0% ROA vs MBRX's -112.5%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MBRX | -10.1% revenue growth vs DBVT's -100.0% |
| Quality / Margins | MBRX | 0.5% margin vs DBVT's 0.3% |
| Stability / Safety | MBRX | Beta 1.22 vs DBVT's 1.26, lower leverage |
| Dividends | MBRX | 0.4% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | MBRX | +149.2% vs DBVT's +110.4% |
| Efficiency (ROA) | DBVT | -89.0% ROA vs MBRX's -112.5% |
MBRX vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDBVTLAGGINGMBRX
MBRXMoleculin Biotech, In…
2leads
DBVTDBV Technologies S.A.
3leads
6 Total Categories
CATEGORYLEADERvs MBRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MBRX1/1
Valuation MetricsMultiples, price ratios, and targets
DBVT2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DBVT5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
MBRX1/1
Income & Cash Flow (Last 12 Months)
MBRX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
MBRX and DBVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | MBRXMoleculin Biotech… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$25M | -$112M |
| Net IncomeAfter-tax profit | -$24M | -$168M |
| Free Cash FlowCash after capex | -$23M | -$151M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +134.5% | +91.5% |
MBRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
DBVT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | MBRXMoleculin Biotech… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $29M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $21M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -0.09x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 1.97x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
DBVT leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
DBVT leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
DBVT delivers a -130.2% return on equity — every $100 of shareholder capital generates $-130 in annual profit, vs $-3 for MBRX. MBRX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs MBRX's 3/9, reflecting mixed financial health.
| Metric | MBRXMoleculin Biotech… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -3.2% | -130.2% |
| ROA (TTM)Return on assets | -112.5% | -89.0% |
| ROICReturn on invested capital | -4.4% | — |
| ROCEReturn on capital employed | -187.1% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.13x |
| Net DebtTotal debt minus cash | -$9M | -$172M |
| Cash & Equiv.Liquid assets | $9M | $194M |
| Total DebtShort + long-term debt | $222,000 | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
DBVT leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $496 for MBRX. Over the past 12 months, MBRX leads with a +149.2% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs MBRX's -40.7% — a key indicator of consistent wealth creation.
| Metric | MBRXMoleculin Biotech… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -31.2% | +4.9% |
| 1-Year ReturnPast 12 months | +149.2% | +110.4% |
| 3-Year ReturnCumulative with dividends | -79.2% | +19.7% |
| 5-Year ReturnCumulative with dividends | -95.0% | -69.1% |
| 10-Year ReturnCumulative with dividends | -99.7% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -40.7% | +6.2% |
DBVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MBRX and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MBRX is the less volatile stock with a 1.22 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs MBRX's 31.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MBRXMoleculin Biotech… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 1.26x |
| 52-Week HighHighest price in past year | $7.98 | $26.18 |
| 52-Week LowLowest price in past year | $0.25 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +31.2% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 48.5 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 110K | 252K |
Evenly matched — MBRX and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
MBRX leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates MBRX as "Buy" and DBVT as "Buy". MBRX is the only dividend payer here at 0.35% yield — a key consideration for income-focused portfolios.
| Metric | MBRXMoleculin Biotech… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $46.33 |
| # AnalystsCovering analysts | 4 | 15 |
| Dividend YieldAnnual dividend ÷ price | +0.4% | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | $0.01 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
MBRX leads this category, winning 1 of 1 comparable metric.
Key Takeaway
DBVT leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). MBRX leads in 2 (Income & Cash Flow, Analyst Outlook). 1 tied.
Best OverallDBV Technologies S.A. (DBVT)Leads 3 of 6 categories
Loading custom metrics...
MBRX vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MBRX or DBVT a better buy right now?
Analysts rate Moleculin Biotech, Inc.
(MBRX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MBRX or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -95. 0% for Moleculin Biotech, Inc. (MBRX). Over 10 years, the gap is even starker: DBVT returned -87. 0% versus MBRX's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MBRX or DBVT?
By beta (market sensitivity over 5 years), Moleculin Biotech, Inc.
(MBRX) is the lower-risk stock at 1. 22β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 3% more volatile than MBRX relative to the S&P 500. On balance sheet safety, Moleculin Biotech, Inc. (MBRX) carries a lower debt/equity ratio of 1% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — MBRX or DBVT?
On earnings-per-share growth, the picture is similar: Moleculin Biotech, Inc.
grew EPS 82. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MBRX or DBVT?
Moleculin Biotech, Inc.
(MBRX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MBRX leads at 0. 0% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — MBRX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MBRX or DBVT?
In this comparison, MBRX (0.
4% yield) pays a dividend. DBVT does not pay a meaningful dividend and should not be held primarily for income.
07Is MBRX or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Moleculin Biotech, Inc.
(MBRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 22)). Both have compounded well over 10 years (MBRX: -99. 7%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MBRX and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.